✦ LIBER ✦

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

✍ Scribed by J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. Wu; J. M. Skolnik; L. Hylander-Gans; A. Osmukhina; D. Huszar; R. S. Herbst

Publisher: Springer
Year: 2011
Tongue: English
Weight: 338 KB
Volume: 69
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-011-1667-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of the safety and pharma

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

A phase I and pharmacokinetics study of

A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors

✍ Josephia R. Muindi; Candace S. Johnson; Donald L. Trump; Renee Christy; Kristie 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 429 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

Safety and pharmacokinetics of high-dose

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study

✍ Mitchell E. Gross; Lawrence Leichman; Elizabeth S. Lowe; Alan Swaisland; David B 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 432 KB

Phase I study to determine the safety an

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors

✍ David S. Hong; James L. Abbruzzese; Karla Bogaard; Yvonne Lassere; Masakazu Fuku 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 2 views

A phase I, open-label, randomized crosso

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicols 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 303 KB